nodes	percent_of_prediction	percent_of_DWPC	metapath
Alprostadil—ABCC5—Fluorouracil—urinary bladder cancer	0.201	0.289	CbGbCtD
Alprostadil—SLCO3A1—Methotrexate—urinary bladder cancer	0.173	0.25	CbGbCtD
Alprostadil—ABCC5—Cisplatin—urinary bladder cancer	0.171	0.246	CbGbCtD
Alprostadil—ABCC4—Fluorouracil—urinary bladder cancer	0.0966	0.139	CbGbCtD
Alprostadil—ABCC4—Methotrexate—urinary bladder cancer	0.0532	0.0766	CbGbCtD
Alprostadil—PTGER2—prostate gland—urinary bladder cancer	0.00692	0.0704	CbGeAlD
Alprostadil—PTGER2—urethra—urinary bladder cancer	0.00463	0.0471	CbGeAlD
Alprostadil—PTGER1—renal system—urinary bladder cancer	0.00447	0.0455	CbGeAlD
Alprostadil—PTGIR—prostate gland—urinary bladder cancer	0.00405	0.0412	CbGeAlD
Alprostadil—PTGER2—female reproductive system—urinary bladder cancer	0.00378	0.0384	CbGeAlD
Alprostadil—PTGER1—female reproductive system—urinary bladder cancer	0.00358	0.0364	CbGeAlD
Alprostadil—SLCO3A1—prostate gland—urinary bladder cancer	0.00358	0.0364	CbGeAlD
Alprostadil—SLCO2A1—prostate gland—urinary bladder cancer	0.00354	0.036	CbGeAlD
Alprostadil—PTGER2—vagina—urinary bladder cancer	0.00342	0.0348	CbGeAlD
Alprostadil—ABCC5—prostate gland—urinary bladder cancer	0.00324	0.033	CbGeAlD
Alprostadil—SLCO3A1—seminal vesicle—urinary bladder cancer	0.00302	0.0308	CbGeAlD
Alprostadil—SLCO2A1—seminal vesicle—urinary bladder cancer	0.003	0.0305	CbGeAlD
Alprostadil—PTGIR—epithelium—urinary bladder cancer	0.00298	0.0303	CbGeAlD
Alprostadil—PTGIR—smooth muscle tissue—urinary bladder cancer	0.00287	0.0292	CbGeAlD
Alprostadil—Dinoprost Tromethamine—HPGDS—urinary bladder cancer	0.0028	0.484	CrCbGaD
Alprostadil—PTGIR—renal system—urinary bladder cancer	0.00276	0.0281	CbGeAlD
Alprostadil—SLCO2A1—epithelium—urinary bladder cancer	0.0026	0.0265	CbGeAlD
Alprostadil—SLCO2B1—prostate gland—urinary bladder cancer	0.00254	0.0258	CbGeAlD
Alprostadil—SLCO3A1—renal system—urinary bladder cancer	0.00244	0.0248	CbGeAlD
Alprostadil—SLCO2A1—renal system—urinary bladder cancer	0.00241	0.0246	CbGeAlD
Alprostadil—SLCO3A1—urethra—urinary bladder cancer	0.00239	0.0244	CbGeAlD
Alprostadil—SLCO2A1—urethra—urinary bladder cancer	0.00237	0.0241	CbGeAlD
Alprostadil—ABCC4—prostate gland—urinary bladder cancer	0.00225	0.0229	CbGeAlD
Alprostadil—PTGIR—female reproductive system—urinary bladder cancer	0.00221	0.0225	CbGeAlD
Alprostadil—PTGER2—lymph node—urinary bladder cancer	0.00221	0.0225	CbGeAlD
Alprostadil—Dinoprostone—HPGDS—urinary bladder cancer	0.00215	0.372	CrCbGaD
Alprostadil—SLCO3A1—female reproductive system—urinary bladder cancer	0.00195	0.0199	CbGeAlD
Alprostadil—SLCO2A1—female reproductive system—urinary bladder cancer	0.00193	0.0197	CbGeAlD
Alprostadil—SLCO3A1—vagina—urinary bladder cancer	0.00177	0.018	CbGeAlD
Alprostadil—SLCO2A1—vagina—urinary bladder cancer	0.00175	0.0178	CbGeAlD
Alprostadil—SLCO2B1—renal system—urinary bladder cancer	0.00173	0.0176	CbGeAlD
Alprostadil—ABCC5—vagina—urinary bladder cancer	0.0016	0.0163	CbGeAlD
Alprostadil—ABCC4—renal system—urinary bladder cancer	0.00153	0.0156	CbGeAlD
Alprostadil—SLCO2B1—female reproductive system—urinary bladder cancer	0.00138	0.0141	CbGeAlD
Alprostadil—PTGIR—lymph node—urinary bladder cancer	0.00129	0.0132	CbGeAlD
Alprostadil—ABCC4—female reproductive system—urinary bladder cancer	0.00123	0.0125	CbGeAlD
Alprostadil—SLCO3A1—lymph node—urinary bladder cancer	0.00114	0.0116	CbGeAlD
Alprostadil—SLCO2A1—lymph node—urinary bladder cancer	0.00113	0.0115	CbGeAlD
Alprostadil—ABCC5—lymph node—urinary bladder cancer	0.00103	0.0105	CbGeAlD
Alprostadil—Dihomo-gamma-linolenic acid—PTGS2—urinary bladder cancer	0.00083	0.144	CrCbGaD
Alprostadil—SLCO2B1—lymph node—urinary bladder cancer	0.00081	0.00824	CbGeAlD
Alprostadil—ABCC4—lymph node—urinary bladder cancer	0.000717	0.0073	CbGeAlD
Alprostadil—PTGER2—Ovarian Infertility Genes—CDK4—urinary bladder cancer	0.0006	0.029	CbGpPWpGaD
Alprostadil—SLCO2A1—SLC-mediated transmembrane transport—SLC14A2—urinary bladder cancer	0.000582	0.0282	CbGpPWpGaD
Alprostadil—SLCO3A1—SLC-mediated transmembrane transport—SLC14A2—urinary bladder cancer	0.000552	0.0267	CbGpPWpGaD
Alprostadil—ABCC4—Fluoropyrimidine Activity—RRM2—urinary bladder cancer	0.000523	0.0253	CbGpPWpGaD
Alprostadil—PTGER2—Prostaglandin Synthesis and Regulation—PTGS2—urinary bladder cancer	0.000452	0.0219	CbGpPWpGaD
Alprostadil—ABCC5—NRF2 pathway—UGT2B7—urinary bladder cancer	0.000444	0.0215	CbGpPWpGaD
Alprostadil—ABCC5—Fluoropyrimidine Activity—TYMS—urinary bladder cancer	0.000436	0.0211	CbGpPWpGaD
Alprostadil—ABCC5—Fluoropyrimidine Activity—ERCC2—urinary bladder cancer	0.000406	0.0196	CbGpPWpGaD
Alprostadil—ABCC5—Fluoropyrimidine Activity—MTHFR—urinary bladder cancer	0.000381	0.0184	CbGpPWpGaD
Alprostadil—SLCO2B1—SLC-mediated transmembrane transport—SLC14A2—urinary bladder cancer	0.00032	0.0155	CbGpPWpGaD
Alprostadil—ABCC4—NRF2 pathway—UGT2B7—urinary bladder cancer	0.000308	0.0149	CbGpPWpGaD
Alprostadil—PTGIR—Prostaglandin Synthesis and Regulation—PTGS2—urinary bladder cancer	0.000305	0.0148	CbGpPWpGaD
Alprostadil—PTGER1—Prostaglandin Synthesis and Regulation—PTGS2—urinary bladder cancer	0.000305	0.0148	CbGpPWpGaD
Alprostadil—ABCC4—Fluoropyrimidine Activity—TYMS—urinary bladder cancer	0.000302	0.0146	CbGpPWpGaD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000296	0.0143	CbGpPWpGaD
Alprostadil—ABCC4—Fluoropyrimidine Activity—ERCC2—urinary bladder cancer	0.000281	0.0136	CbGpPWpGaD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.00028	0.0136	CbGpPWpGaD
Alprostadil—ABCC4—Fluoropyrimidine Activity—MTHFR—urinary bladder cancer	0.000264	0.0128	CbGpPWpGaD
Alprostadil—Diabetes mellitus—Epirubicin—urinary bladder cancer	0.00025	0.00139	CcSEcCtD
Alprostadil—Flushing—Etoposide—urinary bladder cancer	0.000249	0.00138	CcSEcCtD
Alprostadil—Anaemia—Fluorouracil—urinary bladder cancer	0.000249	0.00138	CcSEcCtD
Alprostadil—Muscle spasms—Cisplatin—urinary bladder cancer	0.000245	0.00136	CcSEcCtD
Alprostadil—Abnormal vision—Doxorubicin—urinary bladder cancer	0.000242	0.00134	CcSEcCtD
Alprostadil—Sepsis—Doxorubicin—urinary bladder cancer	0.000241	0.00133	CcSEcCtD
Alprostadil—Cardiac failure congestive—Epirubicin—urinary bladder cancer	0.00024	0.00133	CcSEcCtD
Alprostadil—Cough—Gemcitabine—urinary bladder cancer	0.000239	0.00132	CcSEcCtD
Alprostadil—Lethargy—Methotrexate—urinary bladder cancer	0.000237	0.00132	CcSEcCtD
Alprostadil—Hypertension—Gemcitabine—urinary bladder cancer	0.000236	0.00131	CcSEcCtD
Alprostadil—Anaemia—Cisplatin—urinary bladder cancer	0.000236	0.00131	CcSEcCtD
Alprostadil—Dyspepsia—Thiotepa—urinary bladder cancer	0.000234	0.0013	CcSEcCtD
Alprostadil—Convulsion—Fluorouracil—urinary bladder cancer	0.000233	0.00129	CcSEcCtD
Alprostadil—Diabetes mellitus—Doxorubicin—urinary bladder cancer	0.000231	0.00128	CcSEcCtD
Alprostadil—Discomfort—Gemcitabine—urinary bladder cancer	0.00023	0.00128	CcSEcCtD
Alprostadil—Pain—Thiotepa—urinary bladder cancer	0.000227	0.00126	CcSEcCtD
Alprostadil—Discomfort—Fluorouracil—urinary bladder cancer	0.000226	0.00126	CcSEcCtD
Alprostadil—Back pain—Etoposide—urinary bladder cancer	0.000226	0.00125	CcSEcCtD
Alprostadil—Muscle spasms—Etoposide—urinary bladder cancer	0.000225	0.00125	CcSEcCtD
Alprostadil—Oedema—Gemcitabine—urinary bladder cancer	0.000223	0.00124	CcSEcCtD
Alprostadil—Hypoglycaemia—Epirubicin—urinary bladder cancer	0.000223	0.00124	CcSEcCtD
Alprostadil—Lethargy—Epirubicin—urinary bladder cancer	0.000222	0.00123	CcSEcCtD
Alprostadil—Cardiac failure congestive—Doxorubicin—urinary bladder cancer	0.000222	0.00123	CcSEcCtD
Alprostadil—Infection—Gemcitabine—urinary bladder cancer	0.000222	0.00123	CcSEcCtD
Alprostadil—Convulsion—Cisplatin—urinary bladder cancer	0.000221	0.00123	CcSEcCtD
Alprostadil—Oedema—Fluorouracil—urinary bladder cancer	0.00022	0.00122	CcSEcCtD
Alprostadil—Feeling abnormal—Thiotepa—urinary bladder cancer	0.000219	0.00121	CcSEcCtD
Alprostadil—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.000219	0.00121	CcSEcCtD
Alprostadil—Infection—Fluorouracil—urinary bladder cancer	0.000218	0.00121	CcSEcCtD
Alprostadil—Pain in extremity—Epirubicin—urinary bladder cancer	0.000218	0.00121	CcSEcCtD
Alprostadil—Skin disorder—Gemcitabine—urinary bladder cancer	0.000217	0.0012	CcSEcCtD
Alprostadil—Anaemia—Etoposide—urinary bladder cancer	0.000216	0.0012	CcSEcCtD
Alprostadil—Hyperhidrosis—Gemcitabine—urinary bladder cancer	0.000216	0.0012	CcSEcCtD
Alprostadil—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.000215	0.00119	CcSEcCtD
Alprostadil—Discomfort—Cisplatin—urinary bladder cancer	0.000215	0.00119	CcSEcCtD
Alprostadil—Tachycardia—Fluorouracil—urinary bladder cancer	0.000214	0.00119	CcSEcCtD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000214	0.0103	CbGpPWpGaD
Alprostadil—Abdominal pain—Thiotepa—urinary bladder cancer	0.00021	0.00116	CcSEcCtD
Alprostadil—Body temperature increased—Thiotepa—urinary bladder cancer	0.00021	0.00116	CcSEcCtD
Alprostadil—Hypotension—Gemcitabine—urinary bladder cancer	0.000209	0.00116	CcSEcCtD
Alprostadil—Oedema—Cisplatin—urinary bladder cancer	0.000208	0.00115	CcSEcCtD
Alprostadil—Cardiac arrest—Epirubicin—urinary bladder cancer	0.000207	0.00115	CcSEcCtD
Alprostadil—Infection—Cisplatin—urinary bladder cancer	0.000207	0.00115	CcSEcCtD
Alprostadil—Hypoglycaemia—Doxorubicin—urinary bladder cancer	0.000206	0.00114	CcSEcCtD
Alprostadil—Loss of consciousness—Etoposide—urinary bladder cancer	0.000205	0.00114	CcSEcCtD
Alprostadil—Lethargy—Doxorubicin—urinary bladder cancer	0.000205	0.00114	CcSEcCtD
Alprostadil—Hypotension—Fluorouracil—urinary bladder cancer	0.000205	0.00114	CcSEcCtD
Alprostadil—PTGIR—Thromboxane A2 receptor signaling—RHOA—urinary bladder cancer	0.000205	0.0099	CbGpPWpGaD
Alprostadil—Cough—Etoposide—urinary bladder cancer	0.000204	0.00113	CcSEcCtD
Alprostadil—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.000204	0.00113	CcSEcCtD
Alprostadil—Blood creatinine increased—Epirubicin—urinary bladder cancer	0.000204	0.00113	CcSEcCtD
Alprostadil—Tachycardia—Cisplatin—urinary bladder cancer	0.000203	0.00113	CcSEcCtD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000203	0.00981	CbGpPWpGaD
Alprostadil—Convulsion—Etoposide—urinary bladder cancer	0.000203	0.00112	CcSEcCtD
Alprostadil—Skin disorder—Cisplatin—urinary bladder cancer	0.000202	0.00112	CcSEcCtD
Alprostadil—Hypertension—Etoposide—urinary bladder cancer	0.000202	0.00112	CcSEcCtD
Alprostadil—Pain in extremity—Doxorubicin—urinary bladder cancer	0.000201	0.00112	CcSEcCtD
Alprostadil—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.000201	0.00112	CcSEcCtD
Alprostadil—Hypokalaemia—Epirubicin—urinary bladder cancer	0.000198	0.0011	CcSEcCtD
Alprostadil—Discomfort—Etoposide—urinary bladder cancer	0.000197	0.00109	CcSEcCtD
Alprostadil—Hypotension—Cisplatin—urinary bladder cancer	0.000195	0.00108	CcSEcCtD
Alprostadil—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000193	0.00107	CcSEcCtD
Alprostadil—Cardiac arrest—Doxorubicin—urinary bladder cancer	0.000191	0.00106	CcSEcCtD
Alprostadil—Pain—Gemcitabine—urinary bladder cancer	0.000191	0.00106	CcSEcCtD
Alprostadil—Asthenia—Thiotepa—urinary bladder cancer	0.000191	0.00106	CcSEcCtD
Alprostadil—Infection—Etoposide—urinary bladder cancer	0.00019	0.00105	CcSEcCtD
Alprostadil—Blood creatinine increased—Doxorubicin—urinary bladder cancer	0.000189	0.00105	CcSEcCtD
Alprostadil—Influenza—Epirubicin—urinary bladder cancer	0.000188	0.00104	CcSEcCtD
Alprostadil—Pruritus—Thiotepa—urinary bladder cancer	0.000188	0.00104	CcSEcCtD
Alprostadil—Pain—Fluorouracil—urinary bladder cancer	0.000188	0.00104	CcSEcCtD
Alprostadil—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000187	0.00104	CcSEcCtD
Alprostadil—Upper respiratory tract infection—Methotrexate—urinary bladder cancer	0.000187	0.00104	CcSEcCtD
Alprostadil—Tachycardia—Etoposide—urinary bladder cancer	0.000186	0.00103	CcSEcCtD
Alprostadil—Skin disorder—Etoposide—urinary bladder cancer	0.000185	0.00103	CcSEcCtD
Alprostadil—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000184	0.00102	CcSEcCtD
Alprostadil—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000184	0.00102	CcSEcCtD
Alprostadil—Hypokalaemia—Doxorubicin—urinary bladder cancer	0.000183	0.00102	CcSEcCtD
Alprostadil—Diarrhoea—Thiotepa—urinary bladder cancer	0.000182	0.00101	CcSEcCtD
Alprostadil—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000181	0.001	CcSEcCtD
Alprostadil—Bronchitis—Epirubicin—urinary bladder cancer	0.000181	0.001	CcSEcCtD
Alprostadil—Hypotension—Etoposide—urinary bladder cancer	0.000178	0.000988	CcSEcCtD
Alprostadil—Pain—Cisplatin—urinary bladder cancer	0.000178	0.000987	CcSEcCtD
Alprostadil—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000177	0.000979	CcSEcCtD
Alprostadil—Renal failure—Methotrexate—urinary bladder cancer	0.000176	0.000976	CcSEcCtD
Alprostadil—Dizziness—Thiotepa—urinary bladder cancer	0.000176	0.000974	CcSEcCtD
Alprostadil—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.000175	0.000969	CcSEcCtD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000174	0.00843	CbGpPWpGaD
Alprostadil—Influenza—Doxorubicin—urinary bladder cancer	0.000174	0.000965	CcSEcCtD
Alprostadil—Pollakiuria—Epirubicin—urinary bladder cancer	0.000174	0.000963	CcSEcCtD
Alprostadil—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000174	0.000963	CcSEcCtD
Alprostadil—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000172	0.000951	CcSEcCtD
Alprostadil—ABCC5—NRF2 pathway—NQO1—urinary bladder cancer	0.000171	0.00829	CbGpPWpGaD
Alprostadil—Haematuria—Methotrexate—urinary bladder cancer	0.000171	0.000947	CcSEcCtD
Alprostadil—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.00017	0.00094	CcSEcCtD
Alprostadil—Rash—Thiotepa—urinary bladder cancer	0.000167	0.000928	CcSEcCtD
Alprostadil—Bronchitis—Doxorubicin—urinary bladder cancer	0.000167	0.000928	CcSEcCtD
Alprostadil—Dermatitis—Thiotepa—urinary bladder cancer	0.000167	0.000928	CcSEcCtD
Alprostadil—Headache—Thiotepa—urinary bladder cancer	0.000166	0.000922	CcSEcCtD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000165	0.00799	CbGpPWpGaD
Alprostadil—Renal failure—Epirubicin—urinary bladder cancer	0.000165	0.000914	CcSEcCtD
Alprostadil—Body temperature increased—Cisplatin—urinary bladder cancer	0.000165	0.000913	CcSEcCtD
Alprostadil—Pain—Etoposide—urinary bladder cancer	0.000163	0.000904	CcSEcCtD
Alprostadil—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000163	0.000904	CcSEcCtD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000163	0.00786	CbGpPWpGaD
Alprostadil—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000162	0.000897	CcSEcCtD
Alprostadil—Haemoglobin—Methotrexate—urinary bladder cancer	0.000162	0.000896	CcSEcCtD
Alprostadil—Haemorrhage—Methotrexate—urinary bladder cancer	0.000161	0.000892	CcSEcCtD
Alprostadil—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000161	0.000891	CcSEcCtD
Alprostadil—Asthenia—Gemcitabine—urinary bladder cancer	0.00016	0.000889	CcSEcCtD
Alprostadil—Haematuria—Epirubicin—urinary bladder cancer	0.00016	0.000886	CcSEcCtD
Alprostadil—Pharyngitis—Methotrexate—urinary bladder cancer	0.00016	0.000885	CcSEcCtD
Alprostadil—Pruritus—Gemcitabine—urinary bladder cancer	0.000158	0.000876	CcSEcCtD
Alprostadil—Nausea—Thiotepa—urinary bladder cancer	0.000158	0.000875	CcSEcCtD
Alprostadil—Urethral disorder—Methotrexate—urinary bladder cancer	0.000158	0.000874	CcSEcCtD
Alprostadil—Sinusitis—Epirubicin—urinary bladder cancer	0.000157	0.000872	CcSEcCtD
Alprostadil—Feeling abnormal—Etoposide—urinary bladder cancer	0.000157	0.000872	CcSEcCtD
Alprostadil—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000157	0.00087	CcSEcCtD
Alprostadil—Pruritus—Fluorouracil—urinary bladder cancer	0.000155	0.000862	CcSEcCtD
Alprostadil—ABCC5—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000155	0.00752	CbGpPWpGaD
Alprostadil—Visual impairment—Methotrexate—urinary bladder cancer	0.000155	0.000859	CcSEcCtD
Alprostadil—Bradycardia—Epirubicin—urinary bladder cancer	0.000153	0.00085	CcSEcCtD
Alprostadil—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000153	0.000848	CcSEcCtD
Alprostadil—Renal failure—Doxorubicin—urinary bladder cancer	0.000153	0.000846	CcSEcCtD
Alprostadil—Haemoglobin—Epirubicin—urinary bladder cancer	0.000151	0.000839	CcSEcCtD
Alprostadil—Rhinitis—Epirubicin—urinary bladder cancer	0.000151	0.000837	CcSEcCtD
Alprostadil—Body temperature increased—Etoposide—urinary bladder cancer	0.000151	0.000836	CcSEcCtD
Alprostadil—Abdominal pain—Etoposide—urinary bladder cancer	0.000151	0.000836	CcSEcCtD
Alprostadil—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000151	0.000836	CcSEcCtD
Alprostadil—Haemorrhage—Epirubicin—urinary bladder cancer	0.000151	0.000835	CcSEcCtD
Alprostadil—Diarrhoea—Fluorouracil—urinary bladder cancer	0.00015	0.000833	CcSEcCtD
Alprostadil—PTGIR—Thromboxane A2 receptor signaling—SRC—urinary bladder cancer	0.00015	0.00725	CbGpPWpGaD
Alprostadil—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.00015	0.00083	CcSEcCtD
Alprostadil—Asthenia—Cisplatin—urinary bladder cancer	0.000149	0.000828	CcSEcCtD
Alprostadil—Pharyngitis—Epirubicin—urinary bladder cancer	0.000149	0.000828	CcSEcCtD
Alprostadil—Haematuria—Doxorubicin—urinary bladder cancer	0.000148	0.00082	CcSEcCtD
Alprostadil—Urethral disorder—Epirubicin—urinary bladder cancer	0.000148	0.000818	CcSEcCtD
Alprostadil—Sinusitis—Doxorubicin—urinary bladder cancer	0.000146	0.000807	CcSEcCtD
Alprostadil—Dizziness—Fluorouracil—urinary bladder cancer	0.000145	0.000805	CcSEcCtD
Alprostadil—Visual impairment—Epirubicin—urinary bladder cancer	0.000145	0.000804	CcSEcCtD
Alprostadil—ABCC5—Fluoropyrimidine Activity—TP53—urinary bladder cancer	0.000145	0.007	CbGpPWpGaD
Alprostadil—ABCC5—NRF2 pathway—GSTP1—urinary bladder cancer	0.000143	0.00691	CbGpPWpGaD
Alprostadil—Diarrhoea—Cisplatin—urinary bladder cancer	0.000142	0.00079	CcSEcCtD
Alprostadil—Bradycardia—Doxorubicin—urinary bladder cancer	0.000142	0.000786	CcSEcCtD
Alprostadil—Rash—Gemcitabine—urinary bladder cancer	0.000141	0.000781	CcSEcCtD
Alprostadil—Dermatitis—Gemcitabine—urinary bladder cancer	0.000141	0.00078	CcSEcCtD
Alprostadil—Erythema—Methotrexate—urinary bladder cancer	0.00014	0.000776	CcSEcCtD
Alprostadil—Haemoglobin—Doxorubicin—urinary bladder cancer	0.00014	0.000776	CcSEcCtD
Alprostadil—Headache—Gemcitabine—urinary bladder cancer	0.00014	0.000776	CcSEcCtD
Alprostadil—Flushing—Epirubicin—urinary bladder cancer	0.00014	0.000775	CcSEcCtD
Alprostadil—Rhinitis—Doxorubicin—urinary bladder cancer	0.00014	0.000774	CcSEcCtD
Alprostadil—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000139	0.000772	CcSEcCtD
Alprostadil—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000139	0.000768	CcSEcCtD
Alprostadil—Rash—Fluorouracil—urinary bladder cancer	0.000139	0.000768	CcSEcCtD
Alprostadil—Dermatitis—Fluorouracil—urinary bladder cancer	0.000138	0.000767	CcSEcCtD
Alprostadil—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000138	0.000766	CcSEcCtD
Alprostadil—Headache—Fluorouracil—urinary bladder cancer	0.000138	0.000763	CcSEcCtD
Alprostadil—Asthenia—Etoposide—urinary bladder cancer	0.000137	0.000759	CcSEcCtD
Alprostadil—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000137	0.000757	CcSEcCtD
Alprostadil—Back pain—Methotrexate—urinary bladder cancer	0.000135	0.000751	CcSEcCtD
Alprostadil—Pruritus—Etoposide—urinary bladder cancer	0.000135	0.000748	CcSEcCtD
Alprostadil—ABCC5—Carbohydrate metabolism—ENO2—urinary bladder cancer	0.000134	0.0065	CbGpPWpGaD
Alprostadil—Visual impairment—Doxorubicin—urinary bladder cancer	0.000134	0.000744	CcSEcCtD
Alprostadil—Nausea—Gemcitabine—urinary bladder cancer	0.000133	0.000736	CcSEcCtD
Alprostadil—PTGIR—Thromboxane A2 receptor signaling—EGFR—urinary bladder cancer	0.000131	0.00635	CbGpPWpGaD
Alprostadil—Rash—Cisplatin—urinary bladder cancer	0.000131	0.000728	CcSEcCtD
Alprostadil—ABCC5—NRF2 pathway—GSTM1—urinary bladder cancer	0.000131	0.00635	CbGpPWpGaD
Alprostadil—Dermatitis—Cisplatin—urinary bladder cancer	0.000131	0.000727	CcSEcCtD
Alprostadil—Erythema—Epirubicin—urinary bladder cancer	0.000131	0.000726	CcSEcCtD
Alprostadil—Diarrhoea—Etoposide—urinary bladder cancer	0.000131	0.000724	CcSEcCtD
Alprostadil—Nausea—Fluorouracil—urinary bladder cancer	0.00013	0.000723	CcSEcCtD
Alprostadil—Anaemia—Methotrexate—urinary bladder cancer	0.000129	0.000717	CcSEcCtD
Alprostadil—Flushing—Doxorubicin—urinary bladder cancer	0.000129	0.000717	CcSEcCtD
Alprostadil—Nervousness—Epirubicin—urinary bladder cancer	0.000127	0.000706	CcSEcCtD
Alprostadil—Back pain—Epirubicin—urinary bladder cancer	0.000127	0.000703	CcSEcCtD
Alprostadil—Dizziness—Etoposide—urinary bladder cancer	0.000126	0.000699	CcSEcCtD
Alprostadil—Muscle spasms—Epirubicin—urinary bladder cancer	0.000126	0.000698	CcSEcCtD
Alprostadil—Nausea—Cisplatin—urinary bladder cancer	0.000124	0.000686	CcSEcCtD
Alprostadil—Cough—Methotrexate—urinary bladder cancer	0.000122	0.000677	CcSEcCtD
Alprostadil—Convulsion—Methotrexate—urinary bladder cancer	0.000121	0.000673	CcSEcCtD
Alprostadil—Erythema—Doxorubicin—urinary bladder cancer	0.000121	0.000672	CcSEcCtD
Alprostadil—Anaemia—Epirubicin—urinary bladder cancer	0.000121	0.000671	CcSEcCtD
Alprostadil—Rash—Etoposide—urinary bladder cancer	0.00012	0.000667	CcSEcCtD
Alprostadil—Dermatitis—Etoposide—urinary bladder cancer	0.00012	0.000666	CcSEcCtD
Alprostadil—Headache—Etoposide—urinary bladder cancer	0.00012	0.000663	CcSEcCtD
Alprostadil—ABCC4—NRF2 pathway—NQO1—urinary bladder cancer	0.000119	0.00574	CbGpPWpGaD
Alprostadil—Discomfort—Methotrexate—urinary bladder cancer	0.000118	0.000653	CcSEcCtD
Alprostadil—Nervousness—Doxorubicin—urinary bladder cancer	0.000118	0.000653	CcSEcCtD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000118	0.0057	CbGpPWpGaD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000118	0.00569	CbGpPWpGaD
Alprostadil—Syncope—Epirubicin—urinary bladder cancer	0.000118	0.000651	CcSEcCtD
Alprostadil—Back pain—Doxorubicin—urinary bladder cancer	0.000117	0.00065	CcSEcCtD
Alprostadil—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000117	0.000646	CcSEcCtD
Alprostadil—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000115	0.000639	CcSEcCtD
Alprostadil—Cough—Epirubicin—urinary bladder cancer	0.000114	0.000634	CcSEcCtD
Alprostadil—Convulsion—Epirubicin—urinary bladder cancer	0.000114	0.000629	CcSEcCtD
Alprostadil—Infection—Methotrexate—urinary bladder cancer	0.000114	0.000629	CcSEcCtD
Alprostadil—Nausea—Etoposide—urinary bladder cancer	0.000113	0.000628	CcSEcCtD
Alprostadil—Hypertension—Epirubicin—urinary bladder cancer	0.000113	0.000627	CcSEcCtD
Alprostadil—ABCC5—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000112	0.00543	CbGpPWpGaD
Alprostadil—Anaemia—Doxorubicin—urinary bladder cancer	0.000112	0.000621	CcSEcCtD
Alprostadil—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000112	0.00062	CcSEcCtD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000112	0.0054	CbGpPWpGaD
Alprostadil—Skin disorder—Methotrexate—urinary bladder cancer	0.000111	0.000615	CcSEcCtD
Alprostadil—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.00011	0.000612	CcSEcCtD
Alprostadil—Discomfort—Epirubicin—urinary bladder cancer	0.00011	0.000611	CcSEcCtD
Alprostadil—Dry mouth—Epirubicin—urinary bladder cancer	0.000109	0.000605	CcSEcCtD
Alprostadil—Syncope—Doxorubicin—urinary bladder cancer	0.000109	0.000603	CcSEcCtD
Alprostadil—ABCC4—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000108	0.00521	CbGpPWpGaD
Alprostadil—Oedema—Epirubicin—urinary bladder cancer	0.000107	0.000593	CcSEcCtD
Alprostadil—Hypotension—Methotrexate—urinary bladder cancer	0.000107	0.000592	CcSEcCtD
Alprostadil—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000107	0.000591	CcSEcCtD
Alprostadil—Infection—Epirubicin—urinary bladder cancer	0.000106	0.000589	CcSEcCtD
Alprostadil—Cough—Doxorubicin—urinary bladder cancer	0.000106	0.000587	CcSEcCtD
Alprostadil—Shock—Epirubicin—urinary bladder cancer	0.000105	0.000583	CcSEcCtD
Alprostadil—Convulsion—Doxorubicin—urinary bladder cancer	0.000105	0.000582	CcSEcCtD
Alprostadil—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000105	0.000581	CcSEcCtD
Alprostadil—Hypertension—Doxorubicin—urinary bladder cancer	0.000105	0.00058	CcSEcCtD
Alprostadil—Tachycardia—Epirubicin—urinary bladder cancer	0.000104	0.000579	CcSEcCtD
Alprostadil—Skin disorder—Epirubicin—urinary bladder cancer	0.000104	0.000576	CcSEcCtD
Alprostadil—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000103	0.000573	CcSEcCtD
Alprostadil—Discomfort—Doxorubicin—urinary bladder cancer	0.000102	0.000565	CcSEcCtD
Alprostadil—Dry mouth—Doxorubicin—urinary bladder cancer	0.000101	0.00056	CcSEcCtD
Alprostadil—Dyspepsia—Methotrexate—urinary bladder cancer	0.000101	0.000558	CcSEcCtD
Alprostadil—ABCC4—Fluoropyrimidine Activity—TP53—urinary bladder cancer	0.0001	0.00485	CbGpPWpGaD
Alprostadil—ABCC4—Platelet degranulation—IGF1—urinary bladder cancer	0.0001	0.00484	CbGpPWpGaD
Alprostadil—Hypotension—Epirubicin—urinary bladder cancer	9.99e-05	0.000554	CcSEcCtD
Alprostadil—ABCC4—NRF2 pathway—GSTP1—urinary bladder cancer	9.9e-05	0.00479	CbGpPWpGaD
Alprostadil—Oedema—Doxorubicin—urinary bladder cancer	9.9e-05	0.000549	CcSEcCtD
Alprostadil—Infection—Doxorubicin—urinary bladder cancer	9.83e-05	0.000545	CcSEcCtD
Alprostadil—Pain—Methotrexate—urinary bladder cancer	9.77e-05	0.000542	CcSEcCtD
Alprostadil—Shock—Doxorubicin—urinary bladder cancer	9.74e-05	0.00054	CcSEcCtD
Alprostadil—Thrombocytopenia—Doxorubicin—urinary bladder cancer	9.69e-05	0.000537	CcSEcCtD
Alprostadil—Tachycardia—Doxorubicin—urinary bladder cancer	9.66e-05	0.000535	CcSEcCtD
Alprostadil—Skin disorder—Doxorubicin—urinary bladder cancer	9.61e-05	0.000533	CcSEcCtD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	9.58e-05	0.00463	CbGpPWpGaD
Alprostadil—Hyperhidrosis—Doxorubicin—urinary bladder cancer	9.57e-05	0.00053	CcSEcCtD
Alprostadil—ABCC4—Response to elevated platelet cytosolic Ca2+—IGF1—urinary bladder cancer	9.54e-05	0.00461	CbGpPWpGaD
Alprostadil—Feeling abnormal—Methotrexate—urinary bladder cancer	9.42e-05	0.000522	CcSEcCtD
Alprostadil—Dyspepsia—Epirubicin—urinary bladder cancer	9.41e-05	0.000522	CcSEcCtD
Alprostadil—Hypotension—Doxorubicin—urinary bladder cancer	9.25e-05	0.000513	CcSEcCtD
Alprostadil—ABCC5—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	9.16e-05	0.00443	CbGpPWpGaD
Alprostadil—Pain—Epirubicin—urinary bladder cancer	9.15e-05	0.000507	CcSEcCtD
Alprostadil—ABCC4—NRF2 pathway—GSTM1—urinary bladder cancer	9.1e-05	0.0044	CbGpPWpGaD
Alprostadil—Body temperature increased—Methotrexate—urinary bladder cancer	9.03e-05	0.000501	CcSEcCtD
Alprostadil—Abdominal pain—Methotrexate—urinary bladder cancer	9.03e-05	0.000501	CcSEcCtD
Alprostadil—Feeling abnormal—Epirubicin—urinary bladder cancer	8.81e-05	0.000489	CcSEcCtD
Alprostadil—Dyspepsia—Doxorubicin—urinary bladder cancer	8.71e-05	0.000483	CcSEcCtD
Alprostadil—ABCC5—Disease—GSTO2—urinary bladder cancer	8.69e-05	0.0042	CbGpPWpGaD
Alprostadil—Pain—Doxorubicin—urinary bladder cancer	8.46e-05	0.000469	CcSEcCtD
Alprostadil—Body temperature increased—Epirubicin—urinary bladder cancer	8.45e-05	0.000469	CcSEcCtD
Alprostadil—Abdominal pain—Epirubicin—urinary bladder cancer	8.45e-05	0.000469	CcSEcCtD
Alprostadil—Asthenia—Methotrexate—urinary bladder cancer	8.2e-05	0.000455	CcSEcCtD
Alprostadil—Feeling abnormal—Doxorubicin—urinary bladder cancer	8.15e-05	0.000452	CcSEcCtD
Alprostadil—Pruritus—Methotrexate—urinary bladder cancer	8.09e-05	0.000448	CcSEcCtD
Alprostadil—Body temperature increased—Doxorubicin—urinary bladder cancer	7.82e-05	0.000434	CcSEcCtD
Alprostadil—Abdominal pain—Doxorubicin—urinary bladder cancer	7.82e-05	0.000434	CcSEcCtD
Alprostadil—Diarrhoea—Methotrexate—urinary bladder cancer	7.82e-05	0.000433	CcSEcCtD
Alprostadil—ABCC4—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	7.79e-05	0.00377	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—GSTZ1—urinary bladder cancer	7.68e-05	0.00371	CbGpPWpGaD
Alprostadil—Asthenia—Epirubicin—urinary bladder cancer	7.67e-05	0.000425	CcSEcCtD
Alprostadil—PTGER2—Signaling Pathways—HDAC4—urinary bladder cancer	7.57e-05	0.00366	CbGpPWpGaD
Alprostadil—Pruritus—Epirubicin—urinary bladder cancer	7.57e-05	0.000419	CcSEcCtD
Alprostadil—Dizziness—Methotrexate—urinary bladder cancer	7.56e-05	0.000419	CcSEcCtD
Alprostadil—Diarrhoea—Epirubicin—urinary bladder cancer	7.32e-05	0.000406	CcSEcCtD
Alprostadil—ABCC5—Metabolism—NAT1—urinary bladder cancer	7.28e-05	0.00352	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—GSTO2—urinary bladder cancer	7.28e-05	0.00352	CbGpPWpGaD
Alprostadil—Rash—Methotrexate—urinary bladder cancer	7.21e-05	0.000399	CcSEcCtD
Alprostadil—Dermatitis—Methotrexate—urinary bladder cancer	7.2e-05	0.000399	CcSEcCtD
Alprostadil—Headache—Methotrexate—urinary bladder cancer	7.16e-05	0.000397	CcSEcCtD
Alprostadil—Asthenia—Doxorubicin—urinary bladder cancer	7.1e-05	0.000394	CcSEcCtD
Alprostadil—Dizziness—Epirubicin—urinary bladder cancer	7.07e-05	0.000392	CcSEcCtD
Alprostadil—Pruritus—Doxorubicin—urinary bladder cancer	7e-05	0.000388	CcSEcCtD
Alprostadil—Nausea—Methotrexate—urinary bladder cancer	6.79e-05	0.000376	CcSEcCtD
Alprostadil—Diarrhoea—Doxorubicin—urinary bladder cancer	6.77e-05	0.000375	CcSEcCtD
Alprostadil—ABCC5—Disease—SLC19A1—urinary bladder cancer	6.76e-05	0.00327	CbGpPWpGaD
Alprostadil—Rash—Epirubicin—urinary bladder cancer	6.74e-05	0.000374	CcSEcCtD
Alprostadil—Dermatitis—Epirubicin—urinary bladder cancer	6.74e-05	0.000373	CcSEcCtD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	6.71e-05	0.00325	CbGpPWpGaD
Alprostadil—Headache—Epirubicin—urinary bladder cancer	6.7e-05	0.000371	CcSEcCtD
Alprostadil—ABCC5—Metabolism—UGT2B7—urinary bladder cancer	6.66e-05	0.00322	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—IFNA2—urinary bladder cancer	6.64e-05	0.00321	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PRSS3—urinary bladder cancer	6.58e-05	0.00319	CbGpPWpGaD
Alprostadil—Dizziness—Doxorubicin—urinary bladder cancer	6.54e-05	0.000363	CcSEcCtD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	6.47e-05	0.00313	CbGpPWpGaD
Alprostadil—Nausea—Epirubicin—urinary bladder cancer	6.35e-05	0.000352	CcSEcCtD
Alprostadil—ABCC4—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	6.35e-05	0.00307	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—GLI1—urinary bladder cancer	6.35e-05	0.00307	CbGpPWpGaD
Alprostadil—ABCC5—Disease—HDAC4—urinary bladder cancer	6.28e-05	0.00304	CbGpPWpGaD
Alprostadil—Rash—Doxorubicin—urinary bladder cancer	6.24e-05	0.000346	CcSEcCtD
Alprostadil—Dermatitis—Doxorubicin—urinary bladder cancer	6.23e-05	0.000346	CcSEcCtD
Alprostadil—Headache—Doxorubicin—urinary bladder cancer	6.2e-05	0.000344	CcSEcCtD
Alprostadil—ABCC5—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	6.18e-05	0.00299	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—CYP4B1—urinary bladder cancer	5.99e-05	0.0029	CbGpPWpGaD
Alprostadil—Nausea—Doxorubicin—urinary bladder cancer	5.88e-05	0.000326	CcSEcCtD
Alprostadil—ABCC5—Metabolism—SLC19A1—urinary bladder cancer	5.66e-05	0.00274	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PRSS3—urinary bladder cancer	5.51e-05	0.00267	CbGpPWpGaD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	5.51e-05	0.00267	CbGpPWpGaD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	5.22e-05	0.00253	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—HDAC4—urinary bladder cancer	5.12e-05	0.00247	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—HDAC4—urinary bladder cancer	5.12e-05	0.00247	CbGpPWpGaD
Alprostadil—PTGER2—GPCR ligand binding—CXCL8—urinary bladder cancer	5.11e-05	0.00247	CbGpPWpGaD
Alprostadil—ABCC5—Disease—LIG1—urinary bladder cancer	4.99e-05	0.00241	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—PLAU—urinary bladder cancer	4.71e-05	0.00228	CbGpPWpGaD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	4.53e-05	0.00219	CbGpPWpGaD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	4.53e-05	0.00219	CbGpPWpGaD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—urinary bladder cancer	4.48e-05	0.00217	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—IGF1—urinary bladder cancer	4.44e-05	0.00215	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—TYMP—urinary bladder cancer	4.41e-05	0.00213	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—RBX1—urinary bladder cancer	4.35e-05	0.0021	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	4.29e-05	0.00207	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—GLI1—urinary bladder cancer	4.29e-05	0.00207	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—GLI1—urinary bladder cancer	4.29e-05	0.00207	CbGpPWpGaD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—urinary bladder cancer	4.23e-05	0.00205	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—TSC1—urinary bladder cancer	4.09e-05	0.00198	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—RHOA—urinary bladder cancer	4.07e-05	0.00197	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—NAT2—urinary bladder cancer	3.99e-05	0.00193	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—IFNA2—urinary bladder cancer	3.96e-05	0.00192	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—JAG1—urinary bladder cancer	3.89e-05	0.00188	CbGpPWpGaD
Alprostadil—ABCC4—Ectoderm Differentiation—MYC—urinary bladder cancer	3.89e-05	0.00188	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—CREBBP—urinary bladder cancer	3.89e-05	0.00188	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—IGF1—urinary bladder cancer	3.84e-05	0.00186	CbGpPWpGaD
Alprostadil—ABCC5—Disease—ENO2—urinary bladder cancer	3.81e-05	0.00184	CbGpPWpGaD
Alprostadil—ABCC5—Disease—RBX1—urinary bladder cancer	3.61e-05	0.00175	CbGpPWpGaD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—urinary bladder cancer	3.59e-05	0.00174	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—RHOA—urinary bladder cancer	3.52e-05	0.0017	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—CXCL8—urinary bladder cancer	3.45e-05	0.00167	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—CXCL8—urinary bladder cancer	3.45e-05	0.00167	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—RRM2—urinary bladder cancer	3.44e-05	0.00166	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—IL2—urinary bladder cancer	3.41e-05	0.00165	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—RHOA—urinary bladder cancer	3.29e-05	0.00159	CbGpPWpGaD
Alprostadil—ABCC5—Disease—JAG1—urinary bladder cancer	3.23e-05	0.00156	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—HPGDS—urinary bladder cancer	3.19e-05	0.00154	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—ENO2—urinary bladder cancer	3.19e-05	0.00154	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—S100B—urinary bladder cancer	3.15e-05	0.00153	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—GSTT1—urinary bladder cancer	3.09e-05	0.0015	CbGpPWpGaD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	3.03e-05	0.00147	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—RHOA—urinary bladder cancer	2.99e-05	0.00145	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—SRC—urinary bladder cancer	2.98e-05	0.00144	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—IL2—urinary bladder cancer	2.95e-05	0.00143	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—RBX1—urinary bladder cancer	2.94e-05	0.00142	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—RBX1—urinary bladder cancer	2.94e-05	0.00142	CbGpPWpGaD
Alprostadil—ABCC5—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.89e-05	0.0014	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—CXCL8—urinary bladder cancer	2.89e-05	0.0014	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—NCOR1—urinary bladder cancer	2.83e-05	0.00137	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—PLAU—urinary bladder cancer	2.81e-05	0.00136	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—TSC1—urinary bladder cancer	2.76e-05	0.00134	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—TSC1—urinary bladder cancer	2.76e-05	0.00134	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—IL2—urinary bladder cancer	2.76e-05	0.00134	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—EP300—urinary bladder cancer	2.65e-05	0.00128	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—JAG1—urinary bladder cancer	2.63e-05	0.00127	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—JAG1—urinary bladder cancer	2.63e-05	0.00127	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—CXCL8—urinary bladder cancer	2.62e-05	0.00127	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—SRC—urinary bladder cancer	2.58e-05	0.00125	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—NQO1—urinary bladder cancer	2.57e-05	0.00124	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—IL2—urinary bladder cancer	2.51e-05	0.00121	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—TERT—urinary bladder cancer	2.5e-05	0.00121	CbGpPWpGaD
Alprostadil—ABCC5—Disease—NCOR1—urinary bladder cancer	2.35e-05	0.00114	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—CREBBP—urinary bladder cancer	2.32e-05	0.00112	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—FGFR3—urinary bladder cancer	2.29e-05	0.00111	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—IGF1—urinary bladder cancer	2.29e-05	0.00111	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—ESR1—urinary bladder cancer	2.23e-05	0.00108	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—RHOA—urinary bladder cancer	2.22e-05	0.00108	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—RHOA—urinary bladder cancer	2.22e-05	0.00108	CbGpPWpGaD
Alprostadil—ABCC5—Disease—ERCC2—urinary bladder cancer	2.21e-05	0.00107	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—GSTP1—urinary bladder cancer	2.14e-05	0.00104	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—KRAS—urinary bladder cancer	2.13e-05	0.00103	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—S100B—urinary bladder cancer	2.13e-05	0.00103	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—S100B—urinary bladder cancer	2.13e-05	0.00103	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—RHOA—urinary bladder cancer	2.1e-05	0.00101	CbGpPWpGaD
Alprostadil—ABCC5—Disease—MTHFR—urinary bladder cancer	2.08e-05	0.00101	CbGpPWpGaD
Alprostadil—ABCC5—Disease—TERT—urinary bladder cancer	2.07e-05	0.001	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—RHOA—urinary bladder cancer	2.02e-05	0.000977	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—RHOA—urinary bladder cancer	2.02e-05	0.000977	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.01e-05	0.000971	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—TYMS—urinary bladder cancer	1.99e-05	0.000964	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—GSTM1—urinary bladder cancer	1.97e-05	0.000953	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—NCOR1—urinary bladder cancer	1.97e-05	0.000953	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.95e-05	0.000944	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.95e-05	0.000944	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CREBBP—urinary bladder cancer	1.95e-05	0.000944	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—IGF1—urinary bladder cancer	1.93e-05	0.000932	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—EGFR—urinary bladder cancer	1.92e-05	0.000928	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—NCOR1—urinary bladder cancer	1.91e-05	0.000926	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—NCOR1—urinary bladder cancer	1.91e-05	0.000926	CbGpPWpGaD
Alprostadil—ABCC5—Disease—FGFR3—urinary bladder cancer	1.9e-05	0.00092	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—TP53—urinary bladder cancer	1.9e-05	0.000917	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—GPX1—urinary bladder cancer	1.89e-05	0.000912	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—IL2—urinary bladder cancer	1.87e-05	0.000902	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—IL2—urinary bladder cancer	1.87e-05	0.000902	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—ERCC2—urinary bladder cancer	1.85e-05	0.000896	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—HRAS—urinary bladder cancer	1.81e-05	0.000877	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—KRAS—urinary bladder cancer	1.81e-05	0.000876	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—CXCL8—urinary bladder cancer	1.77e-05	0.000857	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—CXCL8—urinary bladder cancer	1.77e-05	0.000857	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—RHOA—urinary bladder cancer	1.77e-05	0.000854	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—IL2—urinary bladder cancer	1.76e-05	0.000851	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—MTHFR—urinary bladder cancer	1.74e-05	0.000842	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—IL2—urinary bladder cancer	1.69e-05	0.000819	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—IL2—urinary bladder cancer	1.69e-05	0.000819	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—TERT—urinary bladder cancer	1.69e-05	0.000816	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—TERT—urinary bladder cancer	1.69e-05	0.000816	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—ERBB2—urinary bladder cancer	1.63e-05	0.000791	CbGpPWpGaD
Alprostadil—ABCC5—Disease—CREBBP—urinary bladder cancer	1.62e-05	0.000783	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—EP300—urinary bladder cancer	1.58e-05	0.000764	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CXCL8—urinary bladder cancer	1.55e-05	0.00075	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—FGFR3—urinary bladder cancer	1.55e-05	0.000749	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—FGFR3—urinary bladder cancer	1.55e-05	0.000749	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—HRAS—urinary bladder cancer	1.54e-05	0.000745	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—SRC—urinary bladder cancer	1.53e-05	0.000743	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—ESR1—urinary bladder cancer	1.5e-05	0.000728	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—ESR1—urinary bladder cancer	1.5e-05	0.000728	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—IL2—urinary bladder cancer	1.48e-05	0.000717	CbGpPWpGaD
Alprostadil—ABCC5—Disease—RHOA—urinary bladder cancer	1.46e-05	0.000708	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CCND1—urinary bladder cancer	1.44e-05	0.000699	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PPARG—urinary bladder cancer	1.41e-05	0.000683	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—MMP9—urinary bladder cancer	1.4e-05	0.000678	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CDKN1A—urinary bladder cancer	1.4e-05	0.000676	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PTEN—urinary bladder cancer	1.39e-05	0.000674	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—CREBBP—urinary bladder cancer	1.36e-05	0.000656	CbGpPWpGaD
Alprostadil—ABCC5—Disease—ERBB2—urinary bladder cancer	1.36e-05	0.000656	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—EP300—urinary bladder cancer	1.33e-05	0.000643	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PTGS2—urinary bladder cancer	1.33e-05	0.000641	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CREBBP—urinary bladder cancer	1.32e-05	0.000638	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CREBBP—urinary bladder cancer	1.32e-05	0.000638	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—IGF1—urinary bladder cancer	1.3e-05	0.00063	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—IGF1—urinary bladder cancer	1.3e-05	0.00063	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—EGFR—urinary bladder cancer	1.3e-05	0.000627	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—EGFR—urinary bladder cancer	1.3e-05	0.000627	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—SRC—urinary bladder cancer	1.29e-05	0.000625	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—KRAS—urinary bladder cancer	1.27e-05	0.000615	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—KRAS—urinary bladder cancer	1.22e-05	0.000592	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—KRAS—urinary bladder cancer	1.22e-05	0.000592	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—RHOA—urinary bladder cancer	1.19e-05	0.000577	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—RHOA—urinary bladder cancer	1.19e-05	0.000577	CbGpPWpGaD
Alprostadil—ABCC5—Disease—CDKN1A—urinary bladder cancer	1.16e-05	0.000561	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—MYC—urinary bladder cancer	1.16e-05	0.00056	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PTEN—urinary bladder cancer	1.16e-05	0.000559	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—EGFR—urinary bladder cancer	1.13e-05	0.000548	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—TP53—urinary bladder cancer	1.13e-05	0.000546	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PTGS2—urinary bladder cancer	1.11e-05	0.000537	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—ERBB2—urinary bladder cancer	1.1e-05	0.000534	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—ERBB2—urinary bladder cancer	1.1e-05	0.000534	CbGpPWpGaD
Alprostadil—ABCC5—Disease—EP300—urinary bladder cancer	1.1e-05	0.000533	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—HRAS—urinary bladder cancer	1.08e-05	0.000523	CbGpPWpGaD
Alprostadil—ABCC5—Disease—SRC—urinary bladder cancer	1.07e-05	0.000519	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—KRAS—urinary bladder cancer	1.07e-05	0.000518	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CXCL8—urinary bladder cancer	1.05e-05	0.000506	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CXCL8—urinary bladder cancer	1.05e-05	0.000506	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—HRAS—urinary bladder cancer	1.04e-05	0.000503	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—HRAS—urinary bladder cancer	1.04e-05	0.000503	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—IL2—urinary bladder cancer	1e-05	0.000484	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—IL2—urinary bladder cancer	1e-05	0.000484	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CCND1—urinary bladder cancer	9.75e-06	0.000472	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CCND1—urinary bladder cancer	9.75e-06	0.000472	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PTEN—urinary bladder cancer	9.68e-06	0.000468	CbGpPWpGaD
Alprostadil—ABCC5—Disease—MYC—urinary bladder cancer	9.61e-06	0.000465	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—TP53—urinary bladder cancer	9.51e-06	0.00046	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—MMP9—urinary bladder cancer	9.47e-06	0.000458	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MMP9—urinary bladder cancer	9.47e-06	0.000458	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CDKN1A—urinary bladder cancer	9.44e-06	0.000456	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CDKN1A—urinary bladder cancer	9.44e-06	0.000456	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PTEN—urinary bladder cancer	9.41e-06	0.000455	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PTEN—urinary bladder cancer	9.41e-06	0.000455	CbGpPWpGaD
Alprostadil—ABCC5—Disease—EGFR—urinary bladder cancer	9.4e-06	0.000455	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—EP300—urinary bladder cancer	9.23e-06	0.000447	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—HRAS—urinary bladder cancer	9.1e-06	0.00044	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—EP300—urinary bladder cancer	8.98e-06	0.000434	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—EP300—urinary bladder cancer	8.98e-06	0.000434	CbGpPWpGaD
Alprostadil—ABCC5—Disease—KRAS—urinary bladder cancer	8.88e-06	0.000429	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—SRC—urinary bladder cancer	8.73e-06	0.000422	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—SRC—urinary bladder cancer	8.73e-06	0.000422	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MYC—urinary bladder cancer	7.82e-06	0.000378	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—MYC—urinary bladder cancer	7.82e-06	0.000378	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—EGFR—urinary bladder cancer	7.65e-06	0.00037	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—EGFR—urinary bladder cancer	7.65e-06	0.00037	CbGpPWpGaD
Alprostadil—ABCC5—Disease—HRAS—urinary bladder cancer	7.55e-06	0.000365	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—KRAS—urinary bladder cancer	7.23e-06	0.00035	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—KRAS—urinary bladder cancer	7.23e-06	0.00035	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—TP53—urinary bladder cancer	6.42e-06	0.000311	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—TP53—urinary bladder cancer	6.42e-06	0.000311	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—HRAS—urinary bladder cancer	6.14e-06	0.000297	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—HRAS—urinary bladder cancer	6.14e-06	0.000297	CbGpPWpGaD
